Media release: 5 October 2020
Melbourne-based Entoura is now accepting orders for its EMC CBD15 CHEW product.
Available as a CBD isolate product (CBD 15mg/tab), the Entoura formulation is a chewable tablet which has been granted Schedule 4 (S4) status. It is the first CBD chewable tablet on the Australian market, a convenient alternative to the readily prescribed oil solutions.
This is great news for prescribers hoping to access a CBD Isolate for approved patients struggling to manage their conditions with traditional pharmaceuticals. For practitioners who wish to learn more about Entoura’s products, please register to the Entoura Cannabis Support Portal via the website.
Entoura was established by Professor Ian Brighthope, who over 40 years ago founded Nutrition Care Pharmaceuticals, a leader in the formulation and manufacture of therapeutic nutraceutical medicines. Entoura is committed to the development of high-quality innovative therapeutics that are supported by outstanding research programs, validated with clinical evidence and disseminated via exceptional education programs.
Entoura is active in the Medicinal Cannabis industry, supporting medicinal cannabis research, education, manufacturing and patient access
For further media information about Entoura and its products, or for help in access, please contact Entoura.